Immatics (IMTX) Non Operating Income (2019 - 2025)
Immatics (IMTX) posted Non Operating Income of $3.9 million for Q4 2025, down 16.62% sequentially from $4.6 million in Q3 2025, and down 91.47% YoY from $45.3 million in Q4 2024.
Immatics (IMTX) Non Operating Income (2019 - 2025) Analysis & Trends
Immatics has reported Non Operating Income for 7 years, with the latest figure at $3.9 million in Q4 2025.
- Quarterly Non Operating Income fell 91.47% year-over-year to $3.9 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$17.9 million (down 127.84% YoY) and the FY2025 annual result came in at -$18.6 million, down 128.59% from the prior year.
- Non Operating Income slipped to $3.9 million in Q4 2025 per IMTX's latest filing, from $4.6 million in the prior quarter.
- Over five years, Non Operating Income peaked at $45.3 million in Q4 2024 and troughed at -$20.6 million in Q2 2025.
- A 5-year average of $2.9 million and a median of $1.6 million in 2022 frame the typical range for Non Operating Income.
- The sharpest annual moves came in 2022 and 2024: Non Operating Income sank 1182.94% in 2022, then surged 2587.02% in 2024.
- Over 5 years, Non Operating Income stood at -$831666.9 in 2021, then tumbled by 1182.94% to -$10.7 million in 2022, then soared by 115.79% to $1.7 million in 2023, then soared by 2587.02% to $45.3 million in 2024, then plunged by 91.47% to $3.9 million in 2025.
- According to Business Quant data, Non Operating Income over the past three periods registered $3.9 million, $4.6 million, and -$20.6 million for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 234.30 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -139.24 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 12.40 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | -51.63 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -53.64 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Immatics | 1.27 Bn | 719.31 Mn | - | 3.86 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 3.86 Mn |
| Sep 30, 2025 | 4.63 Mn |
| Jun 30, 2025 | -20.63 Mn |
| Mar 31, 2025 | -5.76 Mn |
| Dec 31, 2024 | 45.27 Mn |
| Sep 30, 2024 | -3.15 Mn |
| Jun 30, 2024 | 9.38 Mn |
| Mar 31, 2024 | 12.76 Mn |
| Dec 31, 2023 | 1.68 Mn |
| Sep 30, 2023 | 7.38 Mn |
| Jun 30, 2023 | -11.21 Mn |
| Mar 31, 2023 | 7.17 Mn |
| Dec 31, 2022 | -10.67 Mn |
| Sep 30, 2022 | 1.56 Mn |
| Jun 30, 2022 | 4.08 Mn |
| Mar 31, 2022 | 19.27 Mn |
| Dec 31, 2021 | -831,666.88 |
| Sep 30, 2021 | -4.96 Mn |
| Jun 30, 2021 | -3.78 Mn |
| Mar 31, 2021 | 1.24 Mn |